{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:57:24Z","timestamp":1774573044544,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.vhri.2023.08.004","type":"journal-article","created":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T13:24:06Z","timestamp":1697635446000},"page":"109-117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Early Cost-Utility Analysis of Ataluren and Eteplirsen in the Treatment of Duchenne Muscular Dystrophy in Egypt"],"prefix":"10.1016","volume":"38","author":[{"given":"Zahraa","family":"Shehata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Metry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hoda","family":"Rabea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rasha","family":"El Sherif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Abdelrahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalia","family":"Dawoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vhri.2023.08.004_bib1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"10.1016\/j.vhri.2023.08.004_bib2","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1212\/WNL.0000000000000669","article-title":"The burden of Duchenne muscular dystrophy: an international, cross-sectional study","volume":"83","author":"Landfeldt","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.vhri.2023.08.004_bib3","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13023-014-0210-9","article-title":"Comparative cost of illness analysis and assessment of health care burden of Duchenne and Becker muscular dystrophies in Germany","volume":"9","author":"Schreiber-Katz","year":"2014","journal-title":"Orphanet J Rare Dis"},{"issue":"suppl 1","key":"10.1016\/j.vhri.2023.08.004_bib4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s10198-016-0782-5","article-title":"Social\/economic costs and health-related quality of life in patients with Duchenne muscular dystrophy in Europe","volume":"17","author":"Cavazza","year":"2016","journal-title":"Eur J Heal Econ"},{"key":"10.1016\/j.vhri.2023.08.004_bib5","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.vhri.2022.08.006","article-title":"Estimating societal cost of illness and patients\u2019 quality of life of Duchenne muscular dystrophy in Egypt","volume":"33","author":"Shehata","year":"2023","journal-title":"Value Heal Reg Issues"},{"issue":"9","key":"10.1016\/j.vhri.2023.08.004_bib6","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1007\/s11606-020-05805-2","article-title":"Orphan drugs offer larger health gains but less favorable cost-effectiveness than non-orphan drugs","volume":"35","author":"Chambers","year":"2020","journal-title":"J\u00a0Gen Intern Med"},{"issue":"suppl 2","key":"10.1016\/j.vhri.2023.08.004_bib8","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s10072-022-06085-w","article-title":"Therapeutic opportunities and clinical outcome measures in Duchenne muscular dystrophy","volume":"43","author":"Ricci","year":"2022","journal-title":"Neurol Sci"},{"issue":"9","key":"10.1016\/j.vhri.2023.08.004_bib9","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1002\/acn3.51149","article-title":"Restorative treatments of dystrophin expression in Duchenne muscular dystrophy: a systematic review","volume":"7","author":"Pascual-Morena","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"issue":"14","key":"10.1016\/j.vhri.2023.08.004_bib10","doi-asserted-by":"crossref","first-page":"973","DOI":"10.2217\/cer-2020-0095","article-title":"Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy","volume":"9","author":"Campbell","year":"2020","journal-title":"J\u00a0Comp Eff Res"},{"key":"10.1016\/j.vhri.2023.08.004_bib12","first-page":"235","article-title":"Advances and applications pharmacological profile of viltolarsen for the treatment of Duchenne muscular dystrophy: a Japanese experience","volume":"13","author":"Roshmi","year":"2021","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.vhri.2023.08.004_bib13","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2217\/cer-2021-0196","article-title":"Ataluren delays loss of ambulation and respiratory decline in nonsense mutation Duchenne muscular dystrophy patients","volume":"11","author":"Mcdonald","year":"2022","journal-title":"J\u00a0Comp Eff Res"},{"issue":"6","key":"10.1016\/j.vhri.2023.08.004_bib14","first-page":"989","article-title":"Open-label evaluation of Eteplirsen in patients with Duchenne muscular dystrophy amenable to Exon 51 skipping: PROMOVI Trial","volume":"8","author":"McDonald","year":"2021","journal-title":"J\u00a0Neuromuscul Dis"},{"issue":"1","key":"10.1016\/j.vhri.2023.08.004_bib15","first-page":"39","article-title":"A\u00a0combined prospective and retrospective comparison of long-term functional outcomes suggests delayed loss of ambulation and pulmonary decline with long-term Eteplirsen treatment","volume":"9","author":"Mitelman","year":"2022","journal-title":"J\u00a0Neuromuscul Dis"},{"issue":"1","key":"10.1016\/j.vhri.2023.08.004_bib19","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jval.2022.07.004","article-title":"Challenges for economic evaluations of advanced therapy medicinal products: a systematic review","volume":"26","author":"de Labry-Lima","year":"2023","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.vhri.2023.08.004_bib20","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s40273-016-0461-5","article-title":"Economic evaluation in Duchenne muscular dystrophy: model frameworks\u00a0for cost-effectiveness analysis","volume":"35","author":"Landfeldt","year":"2017","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"10.1016\/j.vhri.2023.08.004_bib21","doi-asserted-by":"crossref","first-page":"S400","DOI":"10.1016\/j.jval.2018.09.2376","article-title":"PRM259-the challenges of estimating multi-state model transitions in rare diseases: informing an economic decision model for Duchenne muscular dystrophy","volume":"21","author":"Hill","year":"2018","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.vhri.2023.08.004_bib22","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management","volume":"9","author":"Bushby","year":"2010","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.vhri.2023.08.004_bib23","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.vhri.2013.06.014","article-title":"Recommendations for reporting pharmacoeconomic evaluations in Egypt","volume":"2","author":"Elsisi","year":"2013","journal-title":"Value Health Reg Issues"},{"key":"10.1016\/j.vhri.2023.08.004_bib24","author":"Rohatgi"},{"issue":"14","key":"10.1016\/j.vhri.2023.08.004_bib25","first-page":"1","article-title":"survHE: survival analysis for health economic evaluation and cost-effectiveness modeling","volume":"95","author":"Baio","year":"2020","journal-title":"J\u00a0Stat Softw"},{"key":"10.1016\/j.vhri.2023.08.004_bib26","doi-asserted-by":"crossref","first-page":"855","DOI":"10.2147\/PPA.S44947","article-title":"Utilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastases","volume":"7","author":"Matza","year":"2013","journal-title":"Patient Prefer Adherence"},{"issue":"6","key":"10.1016\/j.vhri.2023.08.004_bib27","first-page":"575","article-title":"Cost-effectiveness of six months versus 1-year adjuvant trastuzumab in HER2 positive early breast cancer in Egypt","volume":"23","author":"Elsisi","year":"2020","journal-title":"J\u00a0Med Econ"},{"issue":"10","key":"10.1016\/j.vhri.2023.08.004_bib28","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/j.jval.2021.03.007","article-title":"Deriving a preference-based measure for people with Duchenne muscular dystrophy from the DMD-QoL","volume":"24","author":"Rowen","year":"2021","journal-title":"Value Health"},{"issue":"10101","key":"10.1016\/j.vhri.2023.08.004_bib30","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0140-6736(17)31611-2","article-title":"Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"McDonald","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.vhri.2023.08.004_bib33","author":"Fasseeh"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221210992300081X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221210992300081X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:15:17Z","timestamp":1761941717000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221210992300081X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":25,"alternative-id":["S221210992300081X"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2023.08.004","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early Cost-Utility Analysis of Ataluren and Eteplirsen in the Treatment of Duchenne Muscular Dystrophy in Egypt","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2023.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}